Related Experiment Video

Updated: Aug 9, 2026

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
07:50

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

[Antithrombotics (Antithrombin therapy)]

Serdar Payzin1

  • 1Department of Cardiology, Medical Faculty, Ege University, Izmir, Turkey. serdar.payzin@ege.edu.tr

Anadolu Kardiyoloji Dergisi : AKD = the Anatolian Journal of Cardiology
|April 15, 2006
PubMed

Insights

Acute coronary syndromes stem from thrombus on atherosclerotic plaques. Current antithrombin therapies are insufficient, necessitating novel anticoagulant and antiplatelet drugs for improved safety and efficacy.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Hematology

Context:

  • Acute coronary syndromes (ACS) are primarily caused by thrombus formation on atherosclerotic plaques.
  • Antithrombin therapy is the cornerstone treatment for managing thrombosis in ACS.
  • Existing antithrombin agents include vitamin K antagonists, heparins, direct thrombin inhibitors, and factor Xa inhibitors.

Purpose:

  • To review the current landscape of antithrombin therapies for ACS.
  • To highlight the limitations of existing antithrombin agents.
  • To underscore the unmet need for novel antithrombotic and antiplatelet strategies.

Summary:

  • Thrombus formation on atherosclerotic plaques is the main driver of ACS.
  • Current antithrombin therapies, encompassing various drug classes, exhibit incomplete efficacy.
  • There is a persistent need for the development of more effective antithrombin and antiplatelet medications.

Impact:

  • Identifies critical gaps in current antithrombotic treatment paradigms for ACS.
  • Emphasizes the clinical need for innovative pharmacological interventions.
  • Guides future research and development in anticoagulant and antiplatelet drug discovery for cardiovascular diseases.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...